Abstract：
Binge eating disorder (BED) is the most common specific eating disorder (ED). It is frequently associated with attention deficit hyperactivity disorder (ADHD), depression, bipolar disorder (BD), anxiety disorders, alcohol and nicotine use disorder, and obesity. The aim of this narrative review was to summarize the evidence for the pharmacological treatment of BED and its comorbid disorders. We recommend the ADHD medication lisdexamfetamine (LDX) and the antiepileptic and antimigraine drug topiramate for the pharmacological treatment of BED. However, only LDX is approved for the treatment of BED in some countries. Medications to treat diseases frequently comorbid with BED include atomoxetine and LDX for ADHD; citalopram, fluoxetine, sertraline, duloxetine, and venlafaxine for anxiety disorders and depression; aripiprazole for manic episodes of BD; lamotrigine, lirasidone and lumateperone for depressive episodes of BD; naltrexone for alcohol use disorder; bupropion for nicotine use disorder; and liraglutide, semaglutide, and the combination of bupropion and naltrexone for obesity. As obesity is a frequent health consequence of BED, weight gain-inducing medications, such as the atypical antipsychotics olanzapine or clozapine, the novel antidepressant mirtazapine and tricyclic antidepressants, and the mood stabilizer valproate should be avoided where possible. It is currently unclear whether the novel and promising glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptor agonists like tirzepatide and retatrutide help with BED and its comorbidities. However, these compounds have been reported to reduce binge eating in individuals with obesity or overweight.
摘要：
暴食症（BED）是最常见的特定饮食障碍（ED）。它经常与注意力缺陷多动障碍（ADHD）有关，抑郁症,双相情感障碍（BD），焦虑症,酒精和尼古丁使用障碍，和肥胖。这篇叙述性综述的目的是总结BED及其合并症的药物治疗证据。我们建议使用ADHD药物治疗BED的药物治疗，包括Dexamfetamine（LDX）和抗癫痫和抗偏头痛药物托吡酯。然而,在一些国家，只有LDX被批准用于治疗床。治疗经常与BED共病的疾病的药物包括托莫西汀和LDX治疗ADHD；西酞普兰，氟西汀,舍曲林,度洛西汀,和文拉法辛用于焦虑症和抑郁症;阿立哌唑用于BD躁狂发作;拉莫三嗪，利拉西酮和lumateperone用于治疗BD抑郁发作；纳曲酮用于酒精使用障碍；安非他酮用于尼古丁使用障碍；和利拉鲁肽，塞马鲁肽,安非他酮和纳曲酮联合治疗肥胖。由于肥胖是BED常见的健康后果，导致体重增加的药物，如非典型抗精神病药物奥氮平或氯氮平，新型抗抑郁药米氮平和三环抗抑郁药，和心境稳定剂丙戊酸盐应尽可能避免。目前尚不清楚这种新颖而有前途的胰高血糖素，葡萄糖依赖性促胰岛素多肽（GIP），和胰高血糖素样肽1（GLP-1）受体激动剂如替瑞沙肽和retatrutide有助于BED及其合并症。然而,据报道，这些化合物可以减少肥胖或超重个体的暴饮暴食。
